Publications by authors named "Wim Goettsch"

Claim this Profile
C
Coverage with evidence development for medicines with insufficient evidence of clinical benefit: experience from the Netherlands.
Jan-Willem Versteeg, Noraly Stam, Aukje K Mantel-Teeuwisse, Lonneke Timmers, Wim Goettsch

Int J Technol Assess Health Care· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of glycaemic control and quality of life in people with type 2 diabetes using glucose-lowering drugs with machine learning-The Maastricht study.
Nikki C C Werkman, Johannes T H Nielen, José Tapia-Galisteo, Francisco J Somolinos-Simón, Maria Elena Hernando, Wim G Goettsch

Diabetes Obes Metab· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drivers of managed entry agreements to reduce reimbursement challenges of orphan medicinal products: the development of a matrix.
Marcelien H E Callenbach, Sibren van den Berg, Alisa Hulsbosch, Carla E M Hollak, Christine Leopold, Wim G Goettsch

Orphanet J Rare Dis· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preparing for the EU HTA Regulation: Insights from the Dutch Perspective.
Anne Willemsen, Maureen Rutten-van Mölken, Riam Al Dulaimi, Hedi Schelleman, Wim Goettsch

J Mark Access Health Policy· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolving Recommendations for Patient Populations Among Oncology Medicines: A Quantitative and Qualitative Analysis.
Milou A Hogervorst, Rick A Vreman, Theresa A Oduol, Aukje K Mantel-Teeuwisse, Wim G Goettsch

Clin Pharmacol Ther· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Harmonizing HTA Evidence Needs and Expectations: Challenges and Opportunities to Improve Evidence Generation, Ensure Access and Affordability.
Sarah K Emond, Wim G Goettsch, Daniel A Ollendorf

Clin Pharmacol Ther· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analytical Methods for Comparing Uncontrolled Trials With External Controls From Real-World Data: A Systematic Literature Review and Comparison With European Regulatory and Health Technology Assessment Practice.
Milou A Hogervorst, Kanaka V Soman, Helga Gardarsdottir, Wim G Goettsch, Lourens T Bloem

Value Health· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Managed Entry Agreements for High-Cost, One-Off Potentially Curative Therapies: A Framework and Calculation Tool to Determine Their Suitability.
Marcelien H E Callenbach, Rick A Vreman, Christine Leopold, Aukje K Mantel-Teeuwisse, Wim G Goettsch

Pharmacoeconomics· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Roadmap to Innovation of HTA Methods (IHTAM): insights from three case studies of quantitative methods.
Li Jiu, Junfeng Wang, Jan-Willem Versteeg, Yingying Zhang, Lifang Liu, Wim G Goettsch

Int J Technol Assess Health Care· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Uncertainty in Long-Term Relative Effectiveness of Medicines in Health Technology Assessment.
Jan-Willem Versteeg, Rick Vreman, Aukje Mantel-Teeuwisse, Wim Goettsch

Value Health· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Role of Medical Societies and the Relevance of Clinical Perspective in the Evolving EU HTA Process: Insights Generated at the 2023 Fall Convention and Survey of the European Access Academy.
Elaine Julian, Oriol Solà-Morales, Maria João Garcia, Francine Brinkhuis, Mira Pavlovic, Wim Goettsch

J Mark Access Health Policy· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Framework for Multistakeholder Patient Registries in the Field of Rare Diseases: Focus on Neurogenetic Diseases.
Daphne H Schoenmakers, Sibren van den Berg, Lonneke Timmers, Laura A Adang, Tobias Bäumer, Wim G Goettsch

Neurology· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Illustrating the Financial Consequences of Outcome-Based Payment Models From a Payers Perspective: The Case of Autologous Gene Therapy Atidarsagene Autotemcel (Libmeldy®).
Marcelien H E Callenbach, Daphne Schoenmakers, Rick A Vreman, Sylvia Vijgen, Lonneke Timmers, Wim G Goettsch

Value Health· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Healthcare decision-making for tumour-agnostic therapies in Europe: lessons learned.
Milou A Hogervorst, Christine C van Hattem, Gabe S Sonke, Aukje K Mantel-Teeuwisse, Wim G Goettsch

Drug Discov Today· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Creating win-win-win situations with managed entry agreements? Prioritizing gene and cell therapies within the window of opportunity.
Marcelien H E Callenbach, Wim G Goettsch, Aukje K Mantel-Teeuwisse, Mark Trusheim

Drug Discov Today· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Navigating the path towards successful implementation of the EU HTA Regulation: key takeaways from the 2023 Spring Convention of the European Access Academy.
Francine Brinkhuis, Elaine Julian, Hendrika van den Ham, Fabrizio Gianfrate, Valentina Strammiello, Wim Goettsch

Health Res Policy Syst· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increasing uptake through collaboration in the development of core outcome sets: Lessons learned at OMERACT 2023.
Beverley Shea, Jordi Pardo Pardo, Shawna Grosskleg, Dorcas E Beaton, Philip Conaghan, Wim Goettsch

Semin Arthritis Rheum· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lifecycle HTA: promising applications and a framework for implementation. An HTAi Global Policy Forum Task Force report.
Franz B Pichler, Meindert Boysen, Nicole Mittmann, Ramiro Gilardino, Andrew Bruce, Wim G Goettsch

Int J Technol Assess Health Care· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An operationalization framework for lifecycle health technology assessment: a Health Technology Assessment International Global Policy Forum Task Force report.
Franz B Pichler, Meindert Boysen, Nicole Mittmann, Ramiro Gilardino, Andrew Bruce, Wim G Goettsch

Int J Technol Assess Health Care· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A literature review of quality assessment and applicability to HTA of risk prediction models of coronary heart disease in patients with diabetes.
Li Jiu, Junfeng Wang, Francisco Javier Somolinos-Simón, Jose Tapia-Galisteo, Gema García-Sáez, Wim G Goettsch

Diabetes Res Clin Pract· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Inclusive Civil Society Dialogue for Successful Implementation of the EU HTA Regulation: Call to Action to Ensure Appropriate Involvement of Stakeholders and Collaborators.
Thomas Desmet, Elaine Julian, Walter Van Dyck, Isabelle Huys, Steven Simoens, Wim Goettsch

J Mark Access Health Policy· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tools for assessing quality of studies investigating health interventions using real-world data: a literature review and content analysis.
Li Jiu, Michiel Hartog, Junfeng Wang, Rick A Vreman, Olaf H Klungel, Wim G Goettsch

BMJ Open· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Added benefit and revenues of oncology drugs approved by the European Medicines Agency between 1995 and 2020: retrospective cohort study.
Francine Brinkhuis, Wim G Goettsch, Aukje K Mantel-Teeuwisse, Lourens T Bloem

BMJ· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A blueprint for health technology assessment capacity building: lessons learned from Malta.
Katharina Abraham, Ingelin Kvamme, Sylvana Magrin Sammut, Simone de Vries, Tanya Formosa, Wim Goettsch

Int J Technol Assess Health Care· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High cost oncology drugs without proof of added benefit are burdening health systems.
Francine Brinkhuis, Wim G Goettsch, Aukje K Mantel-Teeuwisse, Lourens T Bloem

BMJ· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis